KLRS

Kalaris Therapeutics, Inc.

Price Chart

Latest Quote

$4.30

-0.10 (-2.27%)

Current Price

Previous Close	$4.40
Open	$4.46
Day High	$4.59
Day Low	$4.27
Volume	52,982

Fetched: 2026-06-26T02:24:49

Stock Information

Shares Outstanding	23.79M
Total Debt	$1.41M
Cash Equivalents	$97.22M
Net Income	$-44.10M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$102.31M
EPS (TTM)	$-0.78
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$6.50M
Income	$-44.10M
Book/sh	$2.98
Cash/sh	$4.09
Employees	20

Financial Ratios

Quick Ratio	12.03
Current Ratio	12.19
Debt/Eq	2.06

Returns & Margins

ROA	-27.97%
ROE	-66.60%

Ownership

Insider Ownership	8.81%
Institutional Ownership	77.88%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.64
P/B	1.44

Analyst Data

Recommendation	strong_buy
Target Price	$18.71

Technical Indicators

SMA20	$4.52
SMA50	$5.08
SMA200	$6.68
RSI	40.77
ATR	0.3136

Shares Float	7.22M
Short Float	9.63%
Short Ratio	8.16
Rel Volume	0.70

Performance History

Week	-5.49%
Month	-17.47%
Quarter	-29.68%
6 Months	-57.26%
YTD	-48.19%
Year	+72.69%
3 Years	-96.36%
5 Years	-99.07%
10 Years	-99.26%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-25	$4.30	52,982
2026-06-24	$4.40	50,600
2026-06-23	$4.47	22,100
2026-06-22	$4.40	66,300
2026-06-18	$4.72	235,500
2026-06-17	$4.55	82,500
2026-06-16	$4.37	45,100
2026-06-15	$4.27	83,900
2026-06-12	$4.33	34,300
2026-06-11	$4.36	60,000
2026-06-10	$4.16	47,800
2026-06-09	$4.09	103,700
2026-06-08	$4.17	57,900
2026-06-05	$4.44	141,400
2026-06-04	$4.66	39,500
2026-06-03	$4.72	45,600
2026-06-02	$4.65	99,800
2026-06-01	$4.90	65,400
2026-05-29	$5.27	144,900
2026-05-28	$5.18	40,100
2026-05-27	$5.24	82,200
2026-05-26	$5.21	156,100

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

📰 Latest News

Starbucks upgraded, Doximity downgraded: Wall Street's top analyst calls

The Fly • 2026-05-14T13:45:11Z

We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth Carefully

Simply Wall St. • 2025-11-27T12:58:50Z

Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) biggest owners are private equity firms who got richer after stock soared 24% last week

Simply Wall St. • 2025-09-28T13:44:16Z

Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know

Zacks • 2025-09-01T16:00:02Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$1,443,000	$2,701,000	$687,000	$235,000
Total Expenses	$46,152,000	$51,732,000	$13,464,000	$14,006,000
Other Income Expense	$4,157,000	$-14,734,000	$-548,000	$-1,244,000
Other Non Operating Income Expenses	$3,114,000	$21,200,000	$-855,000	$-1,787,000
Net Non Operating Interest Income Expense	$-1,443,000	$-2,701,000	$-687,000	$-235,000
Interest Expense Non Operating	$1,443,000	$2,701,000	$687,000	$235,000
Operating Expense	$46,152,000	$51,732,000	$13,464,000	$14,006,000
General And Administrative Expense	$15,399,000	$6,690,000	$1,757,000	$2,243,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-43,438,000	$-69,167,000	$-14,699,000	$-15,485,000
Net Interest Income	$-1,443,000	$-2,701,000	$-687,000	$-235,000
Normalized Income	$-44,481,000	$-33,233,000	$-15,006,000	$-16,028,000
Net Income From Continuing And Discontinued Operation	$-43,438,000	$-69,167,000	$-14,699,000	$-15,485,000
Total Operating Income As Reported	$-46,152,000	$-51,732,000	$-13,464,000	$-14,006,000
Net Income Common Stockholders	$-43,438,000	$-69,167,000	$-14,699,000	$-15,485,000
Net Income	$-43,438,000	$-69,167,000	$-14,699,000	$-15,485,000
Net Income Including Noncontrolling Interests	$-43,438,000	$-69,167,000	$-14,699,000	$-15,485,000
Net Income Continuous Operations	$-43,438,000	$-69,167,000	$-14,699,000	$-15,485,000
Pretax Income	$-43,438,000	$-69,167,000	$-14,699,000	$-15,485,000
Special Income Charges	$-186,000	$-38,018,000	-	-
Operating Income	$-46,152,000	$-51,732,000	$-13,464,000	$-14,006,000
Per Share
Diluted EPS	$-2.85	$-3.70	$-11.05	$-11.64
Basic EPS	$-2.85	$-3.70	$-11.05	$-11.64
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-43,025,000	$-30,532,000	$-14,319,000	$-15,793,000
Total Unusual Items	$1,043,000	$-35,934,000	$307,000	$543,000
Total Unusual Items Excluding Goodwill	$1,043,000	$-35,934,000	$307,000	$543,000
Reconciled Depreciation	$13,000	$0	-	-
EBITDA (Bullshit earnings)	$-41,982,000	$-66,466,000	$-14,012,000	$-15,250,000
EBIT	$-41,995,000	$-66,466,000	$-14,012,000	$-15,250,000
Diluted Average Shares	$15,267,817	$18,702,413	$1,330,255	$1,330,255
Basic Average Shares	$15,267,817	$18,702,413	$1,330,255	$1,330,255
Diluted NI Availto Com Stockholders	$-43,438,000	$-69,167,000	$-14,699,000	$-15,485,000
Other Special Charges	$186,000	$38,018,000	-	-
Gain On Sale Of Security	$1,229,000	$2,084,000	$307,000	$543,000
Research And Development	$30,753,000	$45,042,000	$11,707,000	$11,763,000
Selling General And Administration	$15,399,000	$6,690,000	$1,757,000	$2,243,000
Other Gand A	$15,399,000	$6,690,000	$1,757,000	$2,243,000

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$78,814,000	$-96,616,000	$-45,017,000	$-30,272,000
Total Assets	$121,736,000	$6,162,000	$3,333,000	$3,899,000
Total Non Current Assets	$2,927,000	$3,556,000	$0	$0
Other Non Current Assets	$1,452,000	$410,000	-	-
Non Current Deferred Assets	$0	$3,146,000	-	-
Current Assets	$118,809,000	$2,606,000	$3,333,000	$3,899,000
Other Current Assets	$78,000	-	$17,000	$3,000
Prepaid Assets	$749,000	$967,000	$147,000	$837,000
Cash Cash Equivalents And Short Term Investments	$117,982,000	$1,639,000	$3,169,000	$3,059,000
Cash And Cash Equivalents	$98,054,000	$1,639,000	$3,169,000	$3,059,000
Debt
Total Debt	$1,448,000	$19,541,000	-	$3,253,000
Long Term Debt And Capital Lease Obligation	$1,132,000	$0	-	$3,253,000
Current Debt And Capital Lease Obligation	$316,000	$19,541,000	-	-
Net Debt	-	$17,902,000	-	$194,000
Current Debt	-	$19,541,000	-	-
Other Current Borrowings	-	$19,541,000	-	-
Long Term Debt	-	-	-	$3,253,000
Liabilities
Total Liabilities Net Minority Interest	$42,922,000	$102,778,000	$48,350,000	$34,171,000
Total Non Current Liabilities Net Minority Interest	$33,208,000	$78,075,000	$44,408,000	$28,480,000
Other Non Current Liabilities	$32,076,000	$32,076,000	-	-
Current Liabilities	$9,714,000	$24,703,000	$3,942,000	$5,691,000
Payables And Accrued Expenses	$7,797,000	$3,164,000	$3,402,000	$5,395,000
Payables	$1,281,000	$1,560,000	$2,375,000	$2,780,000
Accounts Payable	$1,281,000	$1,560,000	$2,362,000	$2,759,000
Other Current Liabilities	-	$1,407,000	$74,000	$38,000
Derivative Product Liabilities	-	-	$0	$262,000
Equity
Common Stock Equity	$78,814,000	$-96,616,000	$-45,017,000	$-30,272,000
Total Equity Gross Minority Interest	$78,814,000	$-96,616,000	$-45,017,000	$-30,272,000
Stockholders Equity	$78,814,000	$-96,616,000	$-45,017,000	$-30,272,000
Gains Losses Not Affecting Retained Earnings	$6,000	$0	-	-
Retained Earnings	$-159,999,000	$-116,561,000	$-47,394,000	$-32,695,000
Preferred Securities Outside Stock Equity	$0	$45,999,000	$44,408,000	$24,965,000
Other
Ordinary Shares Number	$22,902,418	$18,702,413	$18,702,413	$18,702,413
Share Issued	$22,902,418	$18,702,413	$18,702,413	$18,702,413
Tangible Book Value	$78,814,000	$-96,616,000	$-45,017,000	$-30,272,000
Invested Capital	$78,814,000	$-77,075,000	$-45,017,000	$-27,019,000
Working Capital	$109,095,000	$-22,097,000	$-609,000	$-1,792,000
Capital Lease Obligations	$1,448,000	$0	-	-
Total Capitalization	$78,814,000	$-96,616,000	$-45,017,000	$-27,019,000
Additional Paid In Capital	$238,805,000	$19,945,000	$2,377,000	$2,423,000
Capital Stock	$2,000	$0	$0	$0
Common Stock	$2,000	$0	$0	$0
Long Term Capital Lease Obligation	$1,132,000	$0	-	-
Current Capital Lease Obligation	$316,000	$0	-	-
Pensionand Other Post Retirement Benefit Plans Current	$1,601,000	$591,000	$466,000	$258,000
Current Accrued Expenses	$6,516,000	$1,604,000	$1,027,000	$2,615,000
Net PPE	$1,475,000	$0	-	-
Gross PPE	$1,475,000	$0	-	-
Other Properties	$1,475,000	-	-	-
Other Short Term Investments	$19,928,000	$0	-	-
Dueto Related Parties Current	-	-	$13,000	$21,000

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-38,570,000	$-20,670,000	$-14,132,000	$-9,779,000
Operating Activities
Operating Cash Flow	$-38,370,000	$-20,670,000	$-14,132,000	$-9,779,000
Cash Flow From Continuing Operating Activities	$-38,370,000	$-20,670,000	$-14,132,000	$-9,779,000
Operating Gains Losses	$-1,043,000	$35,934,000	$-307,000	$-543,000
Investing Activities
Capital Expenditure	$-200,000	-	-	-
Investing Cash Flow	$-19,723,000	$0	-	-
Cash Flow From Continuing Investing Activities	$-19,723,000	$0	-	-
Financing Activities
Issuance Of Capital Stock	$42,000,000	$1,591,000	$6,742,000	$8,475,000
Financing Cash Flow	$155,007,000	$19,140,000	$14,242,000	$12,780,000
Cash Flow From Continuing Financing Activities	$155,007,000	$19,140,000	$14,242,000	$12,780,000
Net Other Financing Charges	$97,507,000	$-2,420,000	$1,500,000	-
Net Preferred Stock Issuance	$0	$1,591,000	$6,742,000	$8,475,000
Preferred Stock Issuance	$0	$1,591,000	$6,742,000	$8,475,000
Net Common Stock Issuance	$42,000,000	$0	-	-
Common Stock Issuance	$42,000,000	$0	-	-
Other
Issuance Of Debt	$7,500,000	$19,966,000	$6,000,000	$4,300,000
End Cash Position	$98,553,000	$1,639,000	$3,169,000	$3,059,000
Beginning Cash Position	$1,639,000	$3,169,000	$3,059,000	$58,000
Changes In Cash	$96,914,000	$-1,530,000	$110,000	$3,001,000
Proceeds From Stock Option Exercised	$8,000,000	$3,000	$0	$5,000
Net Issuance Payments Of Debt	$7,500,000	$19,966,000	$6,000,000	$4,300,000
Net Long Term Debt Issuance	$7,500,000	$19,966,000	$6,000,000	$4,300,000
Long Term Debt Issuance	$7,500,000	$19,966,000	$6,000,000	$4,300,000
Net Investment Purchase And Sale	$-19,523,000	$0	-	-
Sale Of Investment	$15,000,000	$0	-	-
Purchase Of Investment	$-34,523,000	$0	-	-
Net PPE Purchase And Sale	$-200,000	$0	-	-
Purchase Of PPE	$-200,000	$0	-	-
Change In Working Capital	$3,430,000	$-2,125,000	$-1,092,000	$3,395,000
Change In Other Current Liabilities	$-81,000	$0	-	-
Change In Other Current Assets	$-355,000	$-410,000	-	-
Change In Payables And Accrued Expense	$2,056,000	$-912,000	$-1,768,000	$3,977,000
Change In Accrued Expense	$2,144,000	$115,000	$-1,366,000	$2,148,000
Change In Payable	$-88,000	$-1,027,000	$-402,000	$1,829,000
Change In Account Payable	$-88,000	$-1,027,000	$-402,000	$1,829,000
Change In Prepaid Assets	$1,810,000	$-803,000	$676,000	$-582,000
Other Non Cash Items	$732,000	$13,793,000	$1,818,000	$2,583,000
Stock Based Compensation	$1,936,000	$895,000	$148,000	$271,000
Depreciation Amortization Depletion	$13,000	$0	-	-
Depreciation And Amortization	$13,000	$0	-	-
Depreciation	$13,000	$0	-	-
Gain Loss On Investment Securities	$-1,229,000	$-2,084,000	$-307,000	$-543,000
Net Income From Continuing Operations	$-43,438,000	$-69,167,000	$-14,699,000	$-15,485,000

Fetched: 2026-06-22